NCT04335383

Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies

Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies From B Lymphocytes of Patients Who Have Been Followed for Infection or Colonization With Pseudomonas Aeruginosa: a Prospective Monocentric Trial

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 30 (estimated)
• Sponsor: University Hospital, Grenoble · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Pseudomonas aeruginosa is a pathogenic bacteria for human, especially in hospital settings. It can sometimes be multi-resistant to many or even to all antibiotics usually used for its treatment. The aim of the study is to isolate and produce therapeutic antibodies against the bacteria Pseudomonas aeruginosa in order to provide an alternative treatment to antibiotics in case of infection with an antibiotic-resistant strain of Pseudomonas aeruginosa.

Conditions

• Pseudomonas Aeruginosa
• Multi-antibiotic Resistance

Interventions

Type	Name	Description
BIOLOGICAL	Isolation of anti-Pseudomonas antibodies from type B lymphocytes	Blood sampling. Isolation of mononuclear cells from human peripheral blood by density gradient centrifugation. Identification of functional anti-Pseudomonas antibodies by ELISA and cellular infection assays.

Timeline

• Start date: 2020-10-05
• Primary completion: 2026-10-01
• Completion: 2026-10-01
• First posted: 2020-04-06
• Last updated: 2025-11-20

Locations

1 site across 1 country: France